Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
Exelixis
University of Pittsburgh
M.D. Anderson Cancer Center
University of Kentucky
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Yale University
National Institutes of Health Clinical Center (CC)
Blue Earth Diagnostics
Istari Oncology, Inc.
MedSIR
Istari Oncology, Inc.
Massachusetts General Hospital
Grupo Español Multidisciplinar de Melanoma
Medical College of Wisconsin
Case Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Virginia Commonwealth University
Boston Children's Hospital
ImmunityBio, Inc.
Ohio State University Comprehensive Cancer Center
University of Virginia
Celgene
Memorial Sloan Kettering Cancer Center
Hoosier Cancer Research Network
Albert Einstein College of Medicine
M.D. Anderson Cancer Center
Stanford University
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
University of Cincinnati
Radiation Therapy Oncology Group
OHSU Knight Cancer Institute
Seagen Inc.
Hoffmann-La Roche
Stanford University
TVAX Biomedical
Eastern Cooperative Oncology Group
Wake Forest University Health Sciences
St. Jude Children's Research Hospital
Pfizer
Duke University
University of Alabama at Birmingham
Alliance for Clinical Trials in Oncology
Karyopharm Therapeutics Inc
Genentech, Inc.